Clinical trials: Alzheimer's
Alzheimer Disease, Amyloid Beta-Protein
Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients
The aim of the study is to investigate whether Florbetaben (BAY94-9172)positron emission tomography (PET) is able to distinguish between subjects with mild cognitive impairment (MCI) progressing to Alzheimer's disease (AD) from…
- Trial name
- NCT01138111
- Testing
- Florbetaben (BAY94-9172)
- Where
- Australia
- Volunteers
- 45 people
- Sponsor
- Lantheus Biosciences Ltd.
Alzheimer's Disease, Dementia
Nutritional Programme for Dementia Elderly Patient
The main objective of this study is the improvement of the quality of life and state of health of elderly people with cognitive deterioration and their families through a weight loss prevention programme.
- Trial name
- NCT00479843
- Testing
- Nutritional programme
- Where
- Spain
- Volunteers
- 946 people
- Sponsor
- Société des Produits Nestlé (SPN)
Alzheimer's Disease
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose.
- Trial name
- REFLECT-3 (NCT00348140)
- Testing
- Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg
- Where
- 194 sites in United States, Australia and 20 more
- Volunteers
- 1,468 people
- Sponsor
- GlaxoSmithKline
Alzheimer's Disease
Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease
The primary purpose of this study is to assess the safety and tolerability of TRx0237 when taken at the same time as acetylcholinesterase inhibitors (i.e., donepezil, galantamine, or rivastigmine) and / or memantine to treat…
- Trial name
- NCT01626391
- Testing
- TRx0237
- Where
- 12 sites in Germany, United Kingdom
- Volunteers
- 9 people
- Sponsor
- TauRx Therapeutics Ltd
Dementia, Alzheimer Disease
Assessing a Novel Virtual Environment That Assists With Activities of Daily Living
This Phase 1 study looks at how a new videogame-based program can help residents and care partners prepare for ADLs in a fun way with minimal risk, potentially reducing escalating problems associated with ADL completions.
- Conditions
- Dementia, Alzheimer Disease, Neurodegenerative Diseases
- Trial name
- NCT05418296
- Testing
- A novel digital health device
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- mandy
Alzheimer's Disease
Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this Phase III open-label extension study is to evaluate the long-term safety of Tramiprosate (3APS) in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00314912
- Testing
- Tramiprosate (3APS)
- Where
- United States
- Volunteers
- 650 people
- Sponsor
- Bellus Health Inc. - a GSK company
Alzheimer Disease, Mild Cognitive Impairment
Flortaucipir PET Imaging in the Preclinical, Prodromal and Dementia Phases of Alzheimer's Disease
A Phase 1 study designed to evaluate imaging characteristics of flortaucipir in the preclinical, prodromal and dementia phases of Alzheimer's disease.
- Trial name
- NCT04468347
- Testing
- Flortaucipir F18, Brain PET scan
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)
The study will evaluate the safety \& efficacy of AC-1204, a ketogenic compound, administered orally on a daily basis for 6 months.
- Trial name
- ALERT (NCT01211782)
- Testing
- caprylic triglyceride, long-chain triglyceride
- Where
- United States
- Sponsor
- Cerecin
Alzheimer's Disease
Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)
Re-read of brain amyloid scans acquired in previous AV-45 clinical studies by readers trained using updated reading methodology.
- Trial name
- NCT01565382
- Testing
- florbetapir F 18
- Volunteers
- 40 people
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects
A Phase 2/3 cross-sectional and longitudinal observational study evaluating imaging characteristics of flortaucipir in control subjects and patients with clinically defined MCI and AD dementia (AD).
- Trial name
- MCI (NCT02016560)
- Testing
- florbetapir F 18, Flortaucipir F18, Brain PET Scan
- Where
- 27 sites in United States
- Volunteers
- 383 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Dementia
Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)
This study is a randomized, double-blind, placebo-controlled phase 3 design aimed at further verifying the safety and efficacy of Wujia Yizhi granules for mild-to-moderate Alzheimer's dementia
- Trial name
- NCT06534723
- Testing
- Wujia Yizhi granules
- Where
- China
- Volunteers
- 570 people
- Sponsor
- Sichuan Jishengtang Pharmaceutical Co., Ltd.
Alzheimer Disease
Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease
The aim of this study is to evaluate the safety, feasibility, tolerability and efficacy of a new buccal film of montelukast in patients with mild to moderate Alzheimer's disease.
- Trial name
- BUENA (NCT03402503)
- Testing
- Montelukast buccal film
- Where
- 12 sites in Canada
- Volunteers
- 52 people
- Sponsor
- IntelGenx Corp.
Alzheimer Disease, Dementia
Jigsawdio Multisensory Platform for People With Mild Cognitive Impairment, Alzheimer's Disease, or Related Dementias
This study will evaluate Jigsawdio, a personalized multisensory jigsaw puzzle platform, for adults aged 60 years and older with mild cognitive impairment or mild dementia.
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment
- Trial name
- NCT07839286
- Testing
- Jigsawdio Multisensory Puzzle Platform, Standard Jigsaw Puzzle Activity
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Callahan-Young LLC DBA Jigsawdio
Alzheimer's Disease
Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients
This study will assess the safety, tolerability and Abeta-specific antibody response of repeated intra-muscular injections of adjuvanted CAD106 in patients with mild Alzheimer's Disease.
- Trial name
- NCT01097096
- Testing
- CAD106, Alum, MF59
- Where
- 31 sites in United States, Belgium and 8 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
The purpose of this study is to: Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after…
- Trial name
- NCT07214727
- Testing
- ALN-5288
- Where
- 13 sites in Canada, Netherlands and 2 more
- Volunteers
- 50 people
- Sponsor
- Alnylam Pharmaceuticals
Alzheimer Disease
Study of ASN51 in Adults With Early Alzheimer's Disease
The main purpose of this study is to evaluate the safety, tolerability, and effect on biomarkers of disease pathophysiology and pathology, pharmacokinetics (PK), and preliminary effects on measures of clinical efficacy of…
- Trial name
- NCT06677203
- Testing
- ASN51
- Where
- 7 sites in United States
- Volunteers
- 123 people
- Sponsor
- Asceneuron S.A.
Alzheimer's Disease
Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers
To study the safety of LY2062430 in patients with mild-to-moderate Alzheimer's disease and in healthy volunteers.
- Trial name
- NCT00329082
- Testing
- LY2062430
- Where
- 6 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Irritation/Irritant
Study in Elderly Alzheimer's Patients to Assess Skin Tolerability, Irritation With 3, 7-Day Applications of DTP-System
This study is designed to assess skin tolerability, skin irritation, and adhesion of the 350 mg Donepezil Transdermal Patch (DTP-system), following 3, 7-day applications to 3 specific areas of the body (upper back, upper middle…
- Trial name
- DTP-System (NCT00916383)
- Testing
- 350 mg Donepezil Transdermal Patch
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- Teikoku Pharma USA, Inc.
Healthy
A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates
The purpose of this study is to assess the effects of single and multiple once daily doses of 50 milligram (mg) of JNJ-54861911 on pharmacokinetics (PK) (study of the way a drug enters and leaves the blood and tissues over time)…
- Trial name
- NCT02211079
- Testing
- JNJ-54861911, Caffeine, Midazolam
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Mild Alzheimer's Disease, Mild Cognitive Impairment
Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease
This is a safety and tolerability study investigating the effect of HPP854 in subjects with mild cognitive impairment or a diagnosis of mild Alzheimer's disease.
- Trial name
- NCT01482013
- Testing
- HPP854
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- High Point Pharmaceuticals, LLC.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.